Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease

Mehmet Coskun, Casper Steenholdt, Nanne K de Boer, Ole Haagen Nielsen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Improving the efficacy and reducing the toxicity of thiopurines and methotrexate (MTX) have been areas of intense basic and clinical research. An increased knowledge on pharmacodynamics and pharmacokinetics of these immunomodulators has optimized treatment strategies in inflammatory bowel disease (IBD). This review focuses on the metabolism and mode of action of thiopurines and MTX, and provides an updated overview of individualized treatment strategies in which efficacy in IBD can be increased without compromising safety. The patient-based monitoring instruments adapted into clinical practice include pretreatment thiopurine S-methyltransferase testing, thiopurine metabolite monitoring, and blood count measurements that may help guiding the dosage to improve clinical outcome. Other approaches for optimizing thiopurine therapy in IBD include combination therapy with allopurinol, 5-aminosalicylates, and/or biologics. Similar strategies are yet to be proven effective in improving the outcome of MTX therapy. Important challenges for the management of IBD in the future relate to individualized dosing of immunomodulators for maximal efficacy with minimal risk of side effects. As low-cost conventional immunomodulators still remain a mainstay in pharmacotherapy of IBD, more research remains warranted, especially to substantiate these tailored management strategies in controlled clinical trials.

Original languageEnglish
Pages (from-to)257-74
Number of pages18
JournalClinical Pharmacokinetics
Volume55
Issue number3
DOIs
Publication statusPublished - Mar 2016

Cite this

Coskun, Mehmet ; Steenholdt, Casper ; de Boer, Nanne K ; Nielsen, Ole Haagen. / Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. In: Clinical Pharmacokinetics. 2016 ; Vol. 55, No. 3. pp. 257-74.
@article{129ba44f87dd467ab7e633a32f2b77d2,
title = "Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease",
abstract = "Improving the efficacy and reducing the toxicity of thiopurines and methotrexate (MTX) have been areas of intense basic and clinical research. An increased knowledge on pharmacodynamics and pharmacokinetics of these immunomodulators has optimized treatment strategies in inflammatory bowel disease (IBD). This review focuses on the metabolism and mode of action of thiopurines and MTX, and provides an updated overview of individualized treatment strategies in which efficacy in IBD can be increased without compromising safety. The patient-based monitoring instruments adapted into clinical practice include pretreatment thiopurine S-methyltransferase testing, thiopurine metabolite monitoring, and blood count measurements that may help guiding the dosage to improve clinical outcome. Other approaches for optimizing thiopurine therapy in IBD include combination therapy with allopurinol, 5-aminosalicylates, and/or biologics. Similar strategies are yet to be proven effective in improving the outcome of MTX therapy. Important challenges for the management of IBD in the future relate to individualized dosing of immunomodulators for maximal efficacy with minimal risk of side effects. As low-cost conventional immunomodulators still remain a mainstay in pharmacotherapy of IBD, more research remains warranted, especially to substantiate these tailored management strategies in controlled clinical trials.",
keywords = "Animals, Drug Monitoring, Humans, Immunosuppressive Agents, Inflammatory Bowel Diseases, Methotrexate, Purines, Journal Article, Review",
author = "Mehmet Coskun and Casper Steenholdt and {de Boer}, {Nanne K} and Nielsen, {Ole Haagen}",
year = "2016",
month = "3",
doi = "10.1007/s40262-015-0316-9",
language = "English",
volume = "55",
pages = "257--74",
journal = "Clinical Pharmacokinetics",
issn = "0312-5963",
publisher = "Adis International Ltd",
number = "3",

}

Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. / Coskun, Mehmet; Steenholdt, Casper; de Boer, Nanne K; Nielsen, Ole Haagen.

In: Clinical Pharmacokinetics, Vol. 55, No. 3, 03.2016, p. 257-74.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease

AU - Coskun, Mehmet

AU - Steenholdt, Casper

AU - de Boer, Nanne K

AU - Nielsen, Ole Haagen

PY - 2016/3

Y1 - 2016/3

N2 - Improving the efficacy and reducing the toxicity of thiopurines and methotrexate (MTX) have been areas of intense basic and clinical research. An increased knowledge on pharmacodynamics and pharmacokinetics of these immunomodulators has optimized treatment strategies in inflammatory bowel disease (IBD). This review focuses on the metabolism and mode of action of thiopurines and MTX, and provides an updated overview of individualized treatment strategies in which efficacy in IBD can be increased without compromising safety. The patient-based monitoring instruments adapted into clinical practice include pretreatment thiopurine S-methyltransferase testing, thiopurine metabolite monitoring, and blood count measurements that may help guiding the dosage to improve clinical outcome. Other approaches for optimizing thiopurine therapy in IBD include combination therapy with allopurinol, 5-aminosalicylates, and/or biologics. Similar strategies are yet to be proven effective in improving the outcome of MTX therapy. Important challenges for the management of IBD in the future relate to individualized dosing of immunomodulators for maximal efficacy with minimal risk of side effects. As low-cost conventional immunomodulators still remain a mainstay in pharmacotherapy of IBD, more research remains warranted, especially to substantiate these tailored management strategies in controlled clinical trials.

AB - Improving the efficacy and reducing the toxicity of thiopurines and methotrexate (MTX) have been areas of intense basic and clinical research. An increased knowledge on pharmacodynamics and pharmacokinetics of these immunomodulators has optimized treatment strategies in inflammatory bowel disease (IBD). This review focuses on the metabolism and mode of action of thiopurines and MTX, and provides an updated overview of individualized treatment strategies in which efficacy in IBD can be increased without compromising safety. The patient-based monitoring instruments adapted into clinical practice include pretreatment thiopurine S-methyltransferase testing, thiopurine metabolite monitoring, and blood count measurements that may help guiding the dosage to improve clinical outcome. Other approaches for optimizing thiopurine therapy in IBD include combination therapy with allopurinol, 5-aminosalicylates, and/or biologics. Similar strategies are yet to be proven effective in improving the outcome of MTX therapy. Important challenges for the management of IBD in the future relate to individualized dosing of immunomodulators for maximal efficacy with minimal risk of side effects. As low-cost conventional immunomodulators still remain a mainstay in pharmacotherapy of IBD, more research remains warranted, especially to substantiate these tailored management strategies in controlled clinical trials.

KW - Animals

KW - Drug Monitoring

KW - Humans

KW - Immunosuppressive Agents

KW - Inflammatory Bowel Diseases

KW - Methotrexate

KW - Purines

KW - Journal Article

KW - Review

U2 - 10.1007/s40262-015-0316-9

DO - 10.1007/s40262-015-0316-9

M3 - Article

VL - 55

SP - 257

EP - 274

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

SN - 0312-5963

IS - 3

ER -